How should a DEXA scan be used to evaluate bisphosphonate therapy for osteoporosis?

dc.contributor.author	Koval, Peter G.	eng
dc.contributor.author	Easterling, Lisa	eng
dc.contributor.author	Pettus, Dawn	eng
dc.contributor.author	Mackler, Leslie	eng
dc.date.issued	2005	eng
dc.description.abstract	If bone density is evaluated after initiating bisphosphonate drug therapy, it should be tested no earlier than 2 years (strength of recommendation [SOR]: B, based on case series of dual energy x-ray absorptiometry [DEXA] scanning precision and bisphosphonate efficacy). Currently no prospective, randomized trials investigate the impact of bone density follow-up testing on osteoporotic patients receiving bisphosphonate therapy.	eng
dc.identifier.uri	http://hdl.handle.net/10355/3299	eng
dc.language	English	eng
dc.publisher	Family Physicians Inquiries Network	eng
dc.relation.ispartofcollection	Clinical Inquiries, 2005 (MU)	eng
dc.relation.ispartofcommunity	University of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network	eng
dc.relation.ispartofseries	Journal of family practice, 54, no. 01 (January 2005): 65+.	eng
dc.rights	OpenAccess.	eng
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.	eng
dc.subject	precision error	eng
dc.subject	dual energy xray absorptiometry	eng
dc.subject	bone density	eng
dc.subject.lcsh	Bone densitometry	eng
dc.subject.lcsh	Osteoporosis -- Treatment	eng
dc.title	How should a DEXA scan be used to evaluate bisphosphonate therapy for osteoporosis?	eng
dc.type	Article	eng

Clinical Inquiries, 2005
The items in this collection constitute volume 54 of Clinical Inquiries.